NEW YORK, Aug. 9, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Enzon Pharmaceuticals, Inc. (OTCQX: ENZN), a pharmaceutical company that receives royalty revenues for licensing arrangements with other companies, has qualified to trade on the OTCQX® Best Market.
Enzon Pharmaceuticals, Inc. begins trading today on OTCQX under the symbol "ENZN." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Enzon Pharmaceuticals to the OTCQX market," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "We look forward to supporting Enzon Pharmaceuticals as a publicly-traded company."
Burns, Figa & Will, P.C. serves as Enzon Pharmaceuticals, Inc.'s OTCQX Advisor, responsible for providing professional guidance on OTCQX requirements.
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron®, Sylatron®, Macugen® and CIMZIA®.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-enzon-pharmaceuticals-inc-to-otcqx-300310747.html
SOURCE OTC Markets Group Inc.